Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
STAT+
Health
Biotech
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

It’s a new day. 10 issues you need to track in biotech in 2018

  • Adam Feuerstein

By Adam Feuerstein Jan. 2, 2018

Reprints
2018 biotech outlook: Sunrise
Adobe

Happy New Year and welcome to 2018. Forget about 2017. That’s in the past.

It’s time to look ahead with a clean slate. To get you started, here are 10 storylines that promise to shape biotech — and move stocks — in the months ahead.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

‘A game-changer’: How Vertex delivered on cystic fibrosis
‘A game-changer’: How Vertex delivered on cystic fibrosis
Flawed herpes testing leads to many false positives —…
Flawed herpes testing leads to many false positives — and needless suffering
Do CRISPR enthusiasts have their head in the sand…
Do CRISPR enthusiasts have their head in the sand about the safety of gene editing?
Patient groups balk at former AstraZeneca official negotiating U.K.-India…
Patient groups balk at former AstraZeneca official negotiating U.K.-India free trade deal
Altimmune’s obesity drug fails to stand out from blockbuster…
Altimmune’s obesity drug fails to stand out from blockbuster treatments in early data
Pharmalittle: FDA official wants to use accelerated approval for…
Pharmalittle: FDA official wants to use accelerated approval for gene therapies; pharma asks Biden for tax…

Comments are closed.

Recommended Stories